Delayed Cerebral Ischemia & Cerebral Vasospasm

Delayed Cerebral Ischemia & Cerebral Vasospasm

Delayed cerebral ischemia ($DCI$) remains the foremost cause of secondary neurological morbidity and mortality in patients who survive initial aneurysmal subarachnoid hemorrhage ($aSAH$). Historically equated solely with luminal narrowing of proximal conducting arteries ("cerebral vasospasm"), contemporary neurocritical care recognizes DCI as a multifaceted neurovascular syndrome that demands structured multimodality monitoring and aggressive, stage-specific interventions.

---

Pathophysiological Distinction: Vasospasm vs DCI

A critical conceptual distinction exists between angiographic vasospasm and delayed cerebral ischemia:

The Multifactorial Mechanisms of DCI

Clinical trials demonstrating that drugs reversing macrovascular vasospasm (e.g., clazosentan, an endothelin receptor antagonist) failed to improve functional neurological outcomes confirmed that large-vessel narrowing is only one component of DCI. DCI is driven by four synergistic microvascular and cellular derangements:

1. Microvascular Constriction & Autoregulatory Failure: Hemoglobin degradation products scavenge endothelial nitric oxide ($NO$) and upregulate endothelin-1, inducing profound constriction of parenchymal resistance arterioles ($< 100\,\mu\text{m}$) that are invisible on conventional angiography.
2. Microvascular Thrombosis: Subarachnoid blood triggers von Willebrand factor release, platelet activation, and localized microvascular microthrombi formation, causing focal capillary plugging and downstream ischemia.
3. Cortical Spreading Depolarization ($CSD$): Waves of massive, slowly propagating ($2\text{--}5\text{ mm/min}$) cellular depolarization sweep across the cerebral cortex. In the setting of compromised neurovascular coupling, CSD triggers paradoxical vasoconstriction ("spreading ischemia") rather than compensatory hyperemia, exhausting cellular ATP reserves.
4. Neuroinflammation & Blood-Brain Barrier ($BBB$) Breakdown: Infiltration of subarachnoid spaces by neutrophils and microglia generates reactive oxygen species ($ROS$), lipid peroxidation, and endothelial swelling.

---

Nimodipine Neuroprotection & Hemodynamic Optimization

Oral nimodipine is the only pharmacological agent proven in randomized clinical trials to improve functional neurological outcomes and reduce cerebral infarction in aSAH.

Clinical Evidence: The BANT Trial

The landmark British Aneurysm Nimodipine Trial (BANT) and subsequent meta-analyses established that enteral nimodipine:

• Reduces the incidence of cerebral infarction by $34\%$
• Reduces poor neurological outcomes and death by $40\%$
• Does NOT prevent or reduce the incidence of large-vessel angiographic vasospasm. Nimodipine's efficacy is mediated by cellular neuroprotection (inhibition of L-type calcium channels attenuating intracellular calcium overload and excitotoxicity) and microvascular dilation.

Administration Guidelines & Troubleshooting Hypotension

• Standard Dosing: $60\text{ mg}$ enterally (or via NG/OG tube) every 4 hours for the usual 21-day course, with clinical adjustments when needed (Class 1, Level A).
• Route Warning: Intravenous nimodipine is strictly prohibited in the United States; inadvertent IV injection of oral nimodipine capsules causes refractory systemic hypotension, cardiovascular collapse, and death.

---

Surveillance Neuromonitoring Modalities

Early detection of impending DCI prior to irreversible infarction is the central goal of ICU surveillance.

[ Daily aSAH Neuromonitoring Protocol ]
                 │
    ┌────────────┼────────────┐
    ▼            ▼            ▼
[ Serial Neuro ] [ Daily TCD ] [ Continuous EEG ]
• Hourly GCS     • MCA MFV     • Alpha-Delta Ratio
• Focal deficit    trends        (ADR) decline
• NIHSS changes  • Lindegaard  • Review raw EEG
                   Ratio         with trends
                 │
                 ▼
[ Neurologic Decline or High-Risk Biomarkers ]
                 │
                 ▼
[ Multimodal Advanced Neuroimaging / Invasive Probes ]
• CT Perfusion: Tmax > 6.0 s / MTT prolongation
• Invasive PbtO2: Tissue PO2 < 20 mmHg (critical < 10 mmHg)
• Microdialysis: Lactate/Pyruvate Ratio (LPR) > 40

Transcranial Doppler ($TCD$) & The Lindegaard Ratio

TCD provides non-invasive, bedside velocity assessments of basal intracranial arteries:

• MCA Mean Flow Velocity ($MFV$):
  • Normal: $< 120\text{ cm/s}$
  • Mild vasospasm: $120\text{--}149\text{ cm/s}$
  • Moderate vasospasm: $150\text{--}199\text{ cm/s}$
  • Severe vasospasm: $\ge 200\text{ cm/s}$ (or rapid daily increase $> 50\text{ cm/s}$ per 24 hours)
• The Lindegaard Ratio ($LR$): Differentiates true macrovascular vasospasm from systemic hyperdynamic flow (hyperemia induced by hypertension or inotropes):

$$\text{Lindegaard Ratio } (LR) = \frac{\text{MCA Mean Flow Velocity}}{\text{Extracranial Internal Carotid Artery } (eICA) \text{ Mean Flow Velocity}}$$

• $LR < 3.0$: Hyperdynamic flow / hyperemia (elevated MCA velocity is driven by systemic cardiac output).
• $LR = 3.0\text{--}6.0$: Mild-to-moderate true macrovascular vasospasm.
• $LR > 6.0$: Severe macrovascular vasospasm.
• Basilar Artery: Evaluated using the basilar-to-extracranial-vertebral velocity ratio (Soustiel/Sviri approach) (Basilar MFV / Extracranial Vertebral MFV); a ratio $> 3.0$ denotes true basilar artery vasospasm.

Advanced Imaging & Invasive Neuromonitoring

• Continuous EEG ($cEEG$): In comatose or deeply sedated patients where clinical examination is uninformative, cEEG identifies ischemia hours before infarction. The primary biomarker is a progressive decrease in the Alpha-Delta Ratio ($ADR$) or total spectral power envelope decline.
• CT Perfusion ($CTP$): Quantitative perfusion maps identify hypoperfused penumbra. Prolongation of $T_{\max} > 6.0\text{ seconds}$ or Mean Transit Time ($MTT > 5.5\text{--}6.0\text{ seconds}$) with preserved or elevated Cerebral Blood Volume ($CBV$) delineates salvageable tissue at risk of DCI.
• Invasive Brain Tissue Oxygenation ($PbtO_2$): A parenchymal polarographic probe measures local oxygen tension. $PbtO_2 < 20\text{ mmHg}$ reflects tissue hypoxia; $PbtO_2 < 10\text{ mmHg}$ indicates critical cellular ischemia requiring immediate physiological escalation.
• Cerebral Microdialysis: Measures local metabolic crisis. A Lactate-to-Pyruvate Ratio ($LPR$) $> 40$ combined with extracellular glucose $< 0.8\text{ mmol/L}$ indicates anaerobic glycolysis and secondary mitochondrial uncoupling.

---

Medical Management: The Death of "Triple-H" & Modern Hemodynamics

Why Historical "Triple-H" Is Obsolete

For decades, empiric "Triple-H" therapy (hypervolemia, hemodilution, hypertension) was dogma. Modern multicenter trials revealed that two of the three components are overtly harmful:

1. Hypervolemia: Prophylactic hypervolemia does not improve cerebral blood flow or functional outcomes. Instead, fluid overloading produces a $15\text{--}25\%$ incidence of severe complications: cardiogenic pulmonary edema, myocardial infarction, iatrogenic hyponatremia, and exacerbation of cerebral edema.
2. Hemodilution: While reducing blood viscosity, intentional hemodilution to hematocrit $< 30\%$ directly diminishes arterial oxygen content ($CaO_2 = 1.34 \times [Hb] \times SaO_2 + 0.003 \times PaO_2$), impairing total cerebral oxygen delivery ($DO_2 = CBF \times CaO_2$) despite increased blood flow.

The Contemporary Paradigm: Euvolemia + Induced Hypertension

Evaluate and Treat Symptomatic DCI

Assess a new deficit promptly for rebleeding, hydrocephalus, seizure, metabolic disturbance, infection, and other causes. Do not assume that a high TCD velocity alone proves symptomatic DCI. Maintain euvolemia rather than prophylactic hypervolemia or hemodilution.

In symptomatic DCI after aneurysm treatment, selected pressure elevation can be beneficial. Norepinephrine is commonly used, but a single agent or exact SBP increment is not mandated by robust comparative evidence. Titrate to the examination and perfusion response while monitoring cardiac and pulmonary tolerance. Do not wait an arbitrary one or two hours to escalate if the patient is deteriorating.

CTA, perfusion imaging, EEG trends, and selected invasive monitoring support the assessment. CTP stroke thresholds are not universally validated DCI cutoffs. Endovascular vasodilators or angioplasty may be reasonable in selected severe vasospasm. The choice, timing, and risk depend on vessel anatomy and clinical response, not a fixed clock or one monitoring number.

Endovascular Rescue Therapies

Patients with DCI refractory to induced hypertension, or those in whom induced hypertension is contraindicated (e.g., severe heart failure, acute myocardial infarction), require emergent catheter-directed rescue therapy.